Press Releases

February 12, 2020

Chimeron Bio Announces Appointment of Dr. Dominique Gouty to its Scientific Advisory Board

PHILADELPHIA–Chimeron Bio, an RNA therapy company based in Philadelphia pioneering a novel class of RNA therapeutics, today announced the appointment of Dr. Dominique (Domi) Gouty to its Scientific Advisory Board. As an expert in drug development and Bioanalytical assessment of gene therapy products, Dr. Gouty will advise the company on drug development strategies to advance Chimeron Bio’s pipeline and help bring transformative drugs to patients in need.

Dr. Gouty brings over 25 years of industry experience and a career spanning research and development (R&D), clinical operation and manufacturing in multiple multinational pharmaceutical organizations such as Eli Lilly (IN, USA) and J&J (Dublin, Ireland), as well as smaller biotech companies and CROs. She most recently served as the Chief Scientific Officer at BioAgilytix, a contract research laboratory where she participated in successfully bringing multiple biologic drugs including gene and cell therapies to final approval by the FDA.

Dr. Gouty is a leading expert in key subjects concerning preclinical and clinical bioanalysis for novel therapeutic biologics and biosimilars. She has published over 150 articles and authored multiple books concerning effective drug delivery routes to robust and rigorous immunoassays. She has extensive experience ensuring strict GLP compliance for bioanalytical assays and has expert knowledge on the evolving FDA, EMA and other regulatory agencies.

“The management and I are delighted to welcome Dominique, a seasoned industry leader and an esteemed bioanalytical expert to Chimeron Bio” said Jolly Mazumdar, founder and CEO of the company.  “Her extensive experience in the assessment of Gene Therapy products aligns strongly with the company’s direction and will be valuable as we progress our current pipeline to the clinic as well as embark on new therapeutic areas.”

“The novel therapeutic approach that Chimeron offers in the space of gene therapy is unmatched, and I am excited to be a part of this state-of-the-art and forward-thinking team.” said Dr. Gouty.  “It will be a pleasure working with this talented team that is dedicated to bringing effective and safe medicines of tomorrow to the market” she said.

About Chimeron Bio

Chimeron Bio is a biotechnology company focused on the research of self-amplifying RNA (saRNA) towards development of novel RNA entities for various diseases. The company is using its proprietary ChaESARTM platform to develop a pipeline in oncology, rare genetic disorders and infectious diseases.  For more information, visit www.chimeron.com


Media Inquiries

Interested in learning more about Chimeron Bio’s novel technology and the work we are doing to develop first-in-class self-amplifying RNA therapeutics?

Reach out to us at contact@chimeronbio.com today.

Follow Us